NasdaqGM - Delayed Quote USD

Verona Pharma plc (VRNA)

Compare
15.69 +0.69 (+4.60%)
At close: June 24 at 4:00 PM EDT
15.75 +0.06 (+0.38%)
After hours: June 24 at 7:10 PM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Dr. David S. Zaccardelli Pharm.D. President, CEO & Executive Director 1.27M -- 1964
Mr. Mark W. Hahn Chief Financial Officer 858.29k -- 1963
Dr. Kathleen A. Rickard M.D. Chief Medical Officer 650.83k -- 1958
Mr. Andrew Fisher General Counsel -- -- 1970
Ms. Victoria Stewart Director of Communications -- -- --
Mr. Matthew Casbon VP of Sales, Marketing & Training -- -- --
Ms. Ostra Jewell Senior Vice President of Human Resources -- -- --
Dr. Tara Rheault M.P.H., Ph.D. Chief Development Officer -- -- 1976
Mr. Christopher Martin Chief Commercial Officer -- -- --
Ms. Caroline Diaz Senior Vice President of Regulatory Affairs -- -- --

Verona Pharma plc

3 More London Riverside
London, SE1 2RE
United Kingdom
44 20 3283 4200 https://www.veronapharma.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
79

Description

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.

Corporate Governance

Verona Pharma plc’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

August 1, 2024 at 6:00 AM UTC - August 5, 2024 at 6:00 AM UTC

Verona Pharma plc Earnings Date

Recent Events

May 10, 2024 at 12:00 AM UTC

10-Q: Periodic Financial Reports

May 9, 2024 at 1:00 PM UTC

Q1 2024 Earnings Call

May 9, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

April 30, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

March 20, 2024 at 12:00 AM UTC

ARS: Annual Report to Shareholders

March 8, 2024 at 12:00 AM UTC

PRE 14A: Proxy Statements

February 29, 2024 at 2:00 PM UTC

Full Year 2023 Earnings Call

February 29, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

February 2, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

January 2, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

Related Tickers